HeartSciences Inc.
HSCSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, HeartSciences Inc. focuses on Medical Devices services and products. HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. The company carries a $8.1M market cap, placing it firmly in the micro-cap category. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis.
Market Cap
$8.1M
Beta
1.79
P/E (TTM)
—
P/E (Fwd)
-0.87
EPS (TTM)
$-4.45
EPS (Fwd)
$-2.83
ROE
-382.3%
ROA
-73.5%
Cash
$3.4M
Total Debt
$3.9M
Free CF
-$4.2M
52W Change
-36.6%
Annual Financials
Cash vs Debt
Where HSCS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, HSCS finished 4.38% above its 150-day moving average ($2.51) and 1.87% below its 200-day moving average ($2.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HSCS overbought or oversold?
At the July 15, 2026 close, HSCS's RSI(14) was 47.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
HeartSciences Inc. carries $3.9M in total debt against $3.4M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$4.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -382.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $14K (2022) to $4K (2025), a 70% decline worth watching.
A beta of 1.79 means HSCS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing HSCS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.